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One of the most important scientific discoveries in the recent
past concerns RNA interference (RNAi), which is a post-tran-
scriptional gene-silencing mechanism induced by small inter-
fering RNA (siRNA) and micro-RNA (miRNA).
[1] RNAi has opened
up new avenues in the development of siRNA and miRNA as
therapeutic agents for various diseases.
[2] The reason for the
large number of reports about chemically modified siRNA is
their potential to enhance nuclease resistance, to prevent
immune activation, to decrease off-target effects, and to im-
prove pharmacokinetic and pharmacodynamic properties, all
of which are important for the application of siRNA as thera-
peutic agents.
[3] Another substantial challenge is siRNA deliv-
ery, because these reagents cannot easily traverse cell mem-
branes because of their size and negative charge.
[4] To date,
the most promising therapeutic approach based on RNAi in-
volves chemically modified siRNA that can resolve some of the
issues mentioned above.
Chemical siRNA modifications belong to four classes—back-
bone, ribose, nucleobase, and terminal modifications—with
ribose modifications being the most common.
[2b] Structurally
simple alterations, such as 2’-OCH3 and 2’-F, lead to significant-
ly enhanced performance of siRNA with diverse target genes,
provided that they are positioned in a site-specific manner.
[3] In
particular, 2’-F modifications possess the extraordinary proper-
ty of being very well accepted onto the guide (antisense)
strand, while most other modifications are much better tolerat-
ed by the passenger (sense) strand.
[5] The guide strand is incor-
porated into the crucial functional particle, the RNA-induced
silencing complex (RISC); thus RNA recognition and discrimina-
tion from non-native counterparts is very stringent.
[6]
We postulated that siRNA with specific 2’-azido groups (2’-
N3) should have the potential for enhanced performance, be-
cause this functional group is small, polar, and supports the
C3’-endo ribose pucker
[7] that is characteristic for an A-form
RNA double helix. Interestingly, this modification has not yet
been explored for siRNA technologies. It is even more surpris-
ing that, to the best of our knowledge, the solid-phase chemi-
cal synthesis of 2’-azido-modified RNA has not yet been de-
scribed.
[8] The prospect of potential siRNA applications, and
also of promising applications in modern bioconjugation
chemistry (such as Staudinger ligation and click chemistry)
[9]
prompted us to take up the challenge of synthesizing these
RNA derivatives (Scheme 1).
Nucleosides that carry an azido group—no matter at which
position—cannot be isolated in the form of stable phosphora-
midite building blocks, the most convenient form for use in
advanced RNA solid-phase synthesis approaches.
[10] This is due
to the inherent reactivity between phosphor-III species and
azides according to the Staudinger reaction. However, we had
experimental indications that this reactivity becomes prevalent
only at very high concentrations of azido-modified nucleoside
phosphoramidites (e.g., upon evaporation of the solvents to
isolate these compounds). This led us to consider the possibili-
ty that strand assembly by phosphoramidite chemistry might
still be feasible (at reasonable phosphoramidite concentra-
tions) once the azide moiety has been incorporated into the
RNA. Additionally, two very recent independent studies, one
on the chemical synthesis of 4’-azidomethyl-thymidine modi-
fied DNA and the other on the circularization of DNA by using
a solid-support bearing an azido linker, encouraged us to
target 2’-azido-RNA synthesis.
[11a,b]
We decided to focus on the 2’-azido-2’-deoxyuridine and the
2’-azido-2’-deoxyadenosine building blocks as 2-chlorophenyl
phosphodiester derivatives, 1 and 2, with the aim of employ-
ing them later in a single cycle of standard RNA phosphotri-
ester coupling for the incorporation into RNA, while strand as-
sembly should follow standard phosphoramidite chemistry.
For building block 1, we started the synthesis with 2,2’-anhy-
drouridine 3 (Scheme 2) which is commercially available or can
Scheme 1. Solid-phase chemical synthesis of RNA with site-specifically 2’-
azido-modified nucleosides, and the potential of these novel RNA derivates
for bioconjugation reactions and siRNA technologies.
[a] M. Aigner, K. Fauster, J. Steger, Prof. Dr. R. Micura
Institute of Organic Chemistry
Center for Molecular Biosciences CMBI, University of Innsbruck
6020 Innsbruck (Austria)
Fax: (+43)507-512-2892
E-mail: ronald.micura@uibk.ac.at
[b] Prof. Dr. M. Hartl, Prof. Dr. K. Bister
Institute of Biochemistry
Center for Molecular Biosciences CMBI, University of Innsbruck
6020 Innsbruck (Austria)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201000646.
Re-use of this article is permitted in accordance with the Terms and Condi-
tions set out at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN) 1439–
4227/homepage/2268_onlineopen.html
ChemBioChem 2011, 12, 47–51   2011 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim 47be obtained from uridine by a single transformation by using
diphenyl carbonate in DMF.
[12] Nucleophilic ring-opening with
in situ-generated lithium azide in DMF furnished the 2’-azido-
2’-deoxyuridine derivative 4.
[13] Subsequently, the 5’-hydroxyl
group was protected as dimethoxytrityl (DMT) ether to form
compound 5.
[14] Conversion into the corresponding phospho-
diester 1 was achieved in good yield by reaction with in situ-
generated 2-chlorophenyl chlorophosphorotriazolide, analo-
gously to a general procedure in the literature.
[15]
For building block 2, we started the synthesis with the tri-
flated adenosine derivative 6, which was readily obtained from
adenosine according to the previously described synthesis to
2’-methylseleno adenosine (Scheme 3).
[16] Treatment of 6 with
lithium azide in DMF furnished key compound 7, followed by
cleavage of the silyl protecting group to give the diol deriva-
tive 8. The 5’-hydroxyl group was then protected as the DMT
ether to form 9. Conversion into the corresponding phospho-
diester 2 was achieved in good yield by treatment with 2-
chlorophenyl chlorophosphorotriazolide.
For the incorporation of the 2’-azido-modified nucleoside
phosphodiester building blocks 1 and 2 into RNA, we conduct-
ed strand assembly by automated standard RNA solid-phase
synthesis with 2’-O-[(Triisopropylsilyl)oxy]methyl (2’-O-TOM)-
protected nucleoside phosphoramidites
[17] up to the position
of the intended azide modification. The synthesis was inter-
rupted after the detritylation step that liberated the terminal
5’-hydroxyl group. Coupling of the phosphodiester building
block, 1 or 2, was achieved by activation with 1-(mesitylene-2-
sulfonyl)-3-nitro-1,2,4-triazole (MSNT) by using two syringes at-
tached to the column for reagent delivery and mixing under
argon.
[18] By using this simple setup (see the Supporting Infor-
mation), coupling yields higher than 95% were achieved. After
manual capping, strand elongation was continued by standard
automated RNA phosphoramidite chemistry. With sequences
of up to about 25 nucleotides, we had no indication (from in-
spection of oligonucleotide by-products by LC-ESI mass spec-
trometry; see also refs. [10b] and [11a,c]) that the ribose 2’-
azido group had reacted with the phosphoramidite moiety
under the coupling conditions. For deprotection, the oligoribo-
nucleotides containing 2’-azido groups were first treated with
syn-2-pyridine aldoxime/tetramethylguanidine in dioxane/
water to cleave the 2-chlorophenyl phosphate protecting
groups.
[18] Then, standard deprotection conditions were ap-
plied by using CH3NH2 in ethanol/water followed by treatment
with 1m tetra-n-butylammonium fluoride (TBAF) in THF. After
purification by anion-exchange HPLC, the expected molecular
weights were confirmed by liquid chromatography ESI (LC-ESI)
mass spectrometry (Table 1, Figure 1).
Next we investigated the influence of the 2’-azido group on
the thermal stability of RNA double helices by using tempera-
ture-dependent UV spectroscopy (Figure 2A). At 150 mm NaCl
and 10 mm Na2HPO4 (pH 7.0), the unmodified hairpin 5’-
GAAGGGCAACCUUCG melted at 72.5 0.58C while the 2’-
azido-modified counterparts, 5’-GAAGGGCAACCU*UCG and 5’-
GAA*GGGCAACCUUCG, displayed Tm values of 71.7 0.58C and
71.6 0.58C, respectively. This demonstrates that the 2’-azido
Scheme 2. Synthesis of the 2’-azido-2’-deoxyuridine 3’-phosphodiester build-
ing block 1 for RNA solid-phase synthesis. Reagents and conditions:
a) 1.8 equiv LiF, 1.8 equiv (CH3)3SiN3,i nN,N,N’,N’-tetramethylethylenediamine
(TMEDA)/DMF 1:1, 1108C, 48 h, 66%; b) 1.5 equiv 4,4’-dimethoxytriphenyl-
methyl chloride (DMT-Cl), in pyridine, RT, 24 h, 69%; c) i: 4 equiv N-methyl-
imidazole, in THF, RT, 5 min; ii: 2.5 equiv 2-chlorophenyl phosphorodichlori-
date, 5.5 equiv 1,2,4-triazole, 5 equiv Et3N, in THF, RT, 10 min, 86%.
Scheme 3. Synthesis of the 2’-azido-2’-deoxyadenosine 3’-phosphodiester
building block 2 for RNA solid-phase synthesis. Reagents and conditions:
a) 5 equiv LiN3, in DMF, RT, 20 h, 86%; b) 1m TBAF, 0.5m CH3COOH, in THF,
RT, 2 h, 71%; c) 1.5 equiv DMT-Cl, in pyridine, RT, 16 h, 64%; d) i: 4 equiv N-
methylimidazole, in THF, RT, 5 min; ii: 2.5 equiv 2-chlorophenyl phosphorodi-
chloridate, 5.5 equiv 1,2,4-triazole, 5 equiv Et3N, in THF, RT, 10 min, 79%.
Table 1. Selection of synthesized 2’-azido-2’-deoxyuridine (U*) and 2’-
azido-2’-deoxyadenosine (A*) containing oligoribonucleotides.
Sequence (5’!3’) Amount
[nmol]
MW calcd
[amu]
MW obs
[amu]
GGU*CGACC 125 2549.6 2549.2
GGUCGA*CC 196 2549.6 2549.2
CCAGGCCU*GG 87 3200.1 3200.2
CCA*GGCCUGG 79 3200.1 3200.2
GAAGGGCAACCU*UCG 173 4839.0 4838.4
GAA*GGGCAACCUUCG 161 4839.0 4838.3
G2UCUCU*GCCA2UA2GACATT 298 6678.1 6677.8
UGUCU2A*U2G2CAGAGAC2TdG 120 6697.1 6696.8
UGUCU*UAUU*G2CAGAGAC2TdG 55 6722.1 6721.5
UGUCU2AUU*G2CA*GAGAC2TdG 68 6722.1 6721.2
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slight steric interference of the moiety with the 3’-phos-
phate.
[7a] Additionally, we examined this hairpin system with
CD spectroscopy: the spectra clearly indicate that the overall
conformation of a typical A-form double helical geometry is re-
tained in the 2’-azido-modified RNA (Figure 2B).
To assess the potential of site-specifically 2’-azido-modified
RNA for bioconjugation reactions
[9] we attached a fluorescence
quencher to the azido group to construct a molecular beacon
(MB).
[19] MBs are widely used probes for the specific detection
of DNA and RNA targets, and their function is based on the
interaction between a fluorescent (F) and a quenching (Q)
moiety (Figure 3A). In the absence of the target, the MB
adopts a hairpin structure that brings F and Q into close prox-
imity resulting in quenching of fluorescence. In contrast, hy-
bridization with the target of the MB leads to separation of F
and Q and thus fluorescence emission. Here we wished to
demonstrate that the attachment of a dye to the 2’-azido posi-
tion can be performed post-synthetically by following one of
the most widespread bioconjugation strategies, the Staudinger
ligation.
[9a,20] We synthesized the Disperse Red 1 (DR1) phos-
phine derivative 10 (see Supporting Information) and then ap-
plied typical Staudinger conditions
[20] in H2O/DMF for ligation
to the 5’-fluorescein-labeled RNA 11 (Figure 3B). With a 100-
fold excess of 10, we observed complete conversion of 11 into
the amide- (12) and the O-methyl imidate (12a) linked DR1-
RNA conjugates (85%), and a minor amount (15%) of the
reduced (nonconjugated) 2’-NH2 RNA derivative of 11 (see the
Supporting Information).
This clearly shows that, despite the relatively high steric hin-
drance of the ribose 2’-azido group in RNA, its reactivity is still
sufficient for efficient chemical ligation. Moreover, the fluores-
cence responses of 12 depicted in Figure 3C demonstrate the
expected functionality for target recognition and for discrimi-
nation from near-cognate sequences.
In order to evaluate the potential of 2’-azido-modified oli-
goribonucleotides in siRNA applications, we employed a model
system for the knockdown of the brain acid soluble protein 1
(BASP1) gene by transient siRNA nucleofection in the chicken
DF-1 cell line by using standard commercial siRNA duplexes as
previously described.
[21a] Expression of the BASP1 gene is spe-
cifically suppressed by the Myc oncoprotein, while the BASP1
protein is an efficient inhibitor of Myc-induced cell transforma-
Figure 1. Characterization of 2’-azido-modified oligoribonucleotides by
anion-exchange HPLC and LC-ESI mass spectrometry. A) 8 nucleotide (nt)
RNA containing 2’-azido-2’-deoxyadenosine. B) 10 nt RNA containing 2’-
azido-2’-deoxyuridine. C) 15 nt RNA containing 2’-azido-2’-deoxyadenosine.
For conditions see the Supporting Information.
Figure 2. Spectroscopic characterization of 2’-azido-modified oligoribo-
nucleotides. A) Overlay of UV melting profiles of GAAGGGCAACCUUCG,
GAAGGGCAACCU*UCG, GAA*GGGCAACCUUCG, cRNA=5 mm; B) Overlay of CD
spectra of GAAGGGCAACCUUCG, GAAGGGCAACCU*UCG, GAA*GGGCAAC-
CUUCG, cRNA=2 mm. Conditions: 10 mm Na2HPO4, 150 mm NaCl, pH 7.0.
U*=2’-azido-2’-deoxyuridine, A*=2’-azido-2’-deoxyadenosine, H=hyper-
chromicity.
Figure 3. Attachment of a fluorescence quencher to RNA with an internal
site-specific ribose 2’-azido group. A) Concept of molecular beacon (MB);
B) Staudinger ligation of the phosphine derivative 10 to RNA 11; C) Time-
dependent fluorescence response of the MB 12 to addition of the target se-
quence 13 (left) and of the near-cognate sequence 14 (right) with double
mismatch discrimination (mismatched nucleobases underlined). Conditions:
cMB=0.5 mm, ctarget=2.5 mm, 100 mm MES·NaOH, 1.0 mm MgCl2, pH 6.5.
lex=490 nm, lem=514 nm. f=fluorescence (emission), t=time.
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[21a] We synthesized ten siRNA duplexes for the Myc target
BASP1 with a single 2’-azido-2’-deoxyuridine or 2’-azido-2’-de-
oxyadenosine modification and the sequence organisation de-
picted in Figure 4A (see also Supporting Information). All the
modified siRNAs caused gene silencing to an extent that was
comparable to that of the unmodified reference duplex (Fig-
ure 4B). Remarkably, the 2’-azido group is very well tolerated
in the guide strand, even when the site of modification is lo-
cated in the seed region or very close to the actual cleavage
site. Moreover, double azido-labeled siRNAs, one embracing
the site of cleavage (SIR Az-U9A13) and another with the modi-
fications at the seed region (SIR Az-U5, U9), also showed effi-
cient silencing activity (Figure 4B). These experiments demon-
strate that the 2’-azido group adds to the limited selection of
modifications (2’-F and 2’-OCH3) that are excellently tolerated
in the guide strand.
[3d,5,6a,22]
In conclusion, the solid-phase synthesis approach presented
here efficiently yields RNA with site-specific 2’-azido groups,
and provides a reliable foundation for a wide range of applica-
tions in modern bioconjugation strategies and siRNA technolo-
gies. Clearly, to evaluate the full potential of this type of modi-
fication, systematic studies of 2’-azido-modified siRNA on nu-
clease resistance, immune activation, off-target effects, toxicity,
membrane permeability, and delivery will be required. We are
confident that, in particular, the small size and the high polari-
ty of the azido group will provide improvements for at least
some of these effects. Moreover, the 2’-azido group in siRNA is
available for the attachment of hydrophobic tags (such as cho-
lesterols, lipids, cofactors, cell-penetrating peptides) to en-
hance delivery properties. Additionally, the attachment of fluo-
rescent dyes to the azido anchor (as exemplified here in the
context of MBs) facilitates the localization and tracking of
siRNA in the cell. Another feature that has to be explored in
future studies of 2’-azido-RNA (and in particular of 2’-azido-
siRNA) is photoreactivity, and whether it can be exploited for
crosslinking to peptide and protein targets. All these aspects
represent the focus of ongoing studies in our laboratory to-
gether with the expansion of the concept towards 2’-azido-2’-
deoxycytidine- and 2’-azido-2’-deoxyguanosine-containing
RNA. At the current state of research, the 2’-azido modification
might prove superior to the more than 35 other types of
chemical modifications that have been tested for their effects
on siRNA performance.
[2] It might also prove useful in the ma-
nipulation of other types of noncoding RNA in the cell.
[23]
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